The results of our net-work meta-analysis suggested that metformin be the most promising intervention to reduce the incidence of neonatal hypoglycemia, LGA, macrosomia, hyperbilirubinemia, anomaly and perinatal death, while insulin and glyburide ranking second and third. This evidence concerns the gene INS and Hyperbilirubinemia.